AstraZeneca

Arcus Biosciences to Participate at Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 1, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, Gemcitabine, CD73, PD-L1, Prostate, List of life sciences, Lymphatic system, NYSE, Arcus, NSCLC, Conference, AstraZeneca, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming September 2021 virtual investor conferences.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming September 2021 virtual investor conferences.
  • A replay of the webcast will be available for at least two weeks following the live event.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
  • For more information about Arcus Biosciences, please visit www.arcusbio.com .

New Employee Elected Director to the board of Zealand Pharma A/S

Retrieved on: 
Wednesday, September 1, 2021
DK, Boehringer Ingelheim, Diabetes, Board, Nasdaq, Zealand Pharma, Adult, AstraZeneca, Patient, Hypoglycemia, Pharmaceutical industry

Copenhagen, DK and Boston, MA, U.S. September 1, 2021 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, U.S. September 1, 2021 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no.
  • Anneline Nansen has been instated as an employee elected member of the Board of Directors of Zealand effective as of 1 September 2021.
  • Anneline Nansen was elected as the first alternate employee representative in 2020 and will replace Gertrud Koefoed Rasmussen who stepped down from her position as the employee elected board member on 31 August 2021.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.

Transgene Participates in New Cancer Research Consortium

Retrieved on: 
Wednesday, September 1, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Partnership, Gold, Growth, Cancer, EFPIA, Adoption, Innovative Medicines Initiative, Potyvirus, Method, Neoplasm, Research, Drug discovery, Drug resistance, Risk, AMF, Marketing, Cell, Forward-looking statement, Immunotherapy, TNG, Precision medicine, Mortality, Ambrosius Hubrecht, Failure, Euronext Paris, AstraZeneca, NEC, IMI, Benchmarking, Vaccination, Workflow, Artificial intelligence, Pharmaceutical industry, Vaccine

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of PERSIST-SEQ, a new international consortium of academic and industrial leaders in the field of cancer research.

Key Points: 
  • Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of PERSIST-SEQ, a new international consortium of academic and industrial leaders in the field of cancer research.
  • Cancer takes 9.6 million lives each year, 90% of which result from untreatable cancer relapse occurring after initially effective treatment.
  • Jean-Marc Balloul, Director Innovation & Partnership at Transgene, added: We are proud to participate in the PERSIST-SEQ consortium and contribute to the deciphering of immunotherapeutic resistance in cancer cells.
  • The ultimate goal of the PERSIST-SEQ consortium is to improve the understanding of therapeutic resistance in cancer and create effective strategies to improve cancer treatment and prevent drug resistance.

INOVIO to Present at Upcoming Investor Conferences in September

Retrieved on: 
Wednesday, September 1, 2021
National Institute of Allergy and Infectious Diseases, Epidemic, Walter Reed Army Institute of Research, HPV, University, HIV Vaccine Trials Network, International Vaccine Institute, Infection, Cancer, U.S. Securities and Exchange Commission, Technology, Coalition for Epidemic Preparedness Innovations, Partner, DNA, Radiation, Bill & Melinda Gates Foundation, Regeneron Pharmaceuticals, Cell, National Cancer Institute, Forward-looking statement, Coalition, Safety, National, Wistar Institute, University of Pennsylvania, Bill, National Institutes of Health, Annual report, COVID-19, National Institute, Thermo Fisher Scientific, AstraZeneca, Security (finance), Pharmaceutical industry

Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at https://ir.inovio.com/events-and-presentations/default.aspx .

Key Points: 
  • Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at https://ir.inovio.com/events-and-presentations/default.aspx .
  • INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV.
  • INOVIO is the first company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response.
  • INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea.

Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, September 1, 2021
Company, Terminology, Gastrointestinal tract, Private Securities Litigation Reform Act, ICON plc, U.S. Securities and Exchange Commission, Immunology, Abington Hospital–Jefferson Health, Technology, GLOBE, SEC, Knowledge, DRN, Research, CMO, Nasdaq, Doctor of Philosophy, Food, Time, Cell, Internal medicine, Forward-looking statement, Biotechnology, Clinical trial, Private practice, Safety, CD34, Patient, Caladrius Biosciences, ICON, Kidney disease, Drug development, Neuroscience, AstraZeneca, Security (finance), Degenerative disease, Medical device, Pharmaceutical industry

BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Companys Chief Medical Officer (CMO).

Key Points: 
  • BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Companys Chief Medical Officer (CMO).
  • Dr. Buck joins Caladrius from ICON plc (ICON), a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries.
  • We are delighted to welcome Dr. Buck to Caladrius, said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease.

Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development

Retrieved on: 
Wednesday, September 1, 2021
Industry, Company, Liver, RNA interference, U.S. Securities and Exchange Commission, Gene, Sirna Therapeutics, Research, RNA, Private Securities Litigation Reform Act, Therapy, Anemia, Pathology, Low-density lipoprotein, Mallinckrodt, Annual report, AstraZeneca, Vaccine, Security (finance), Pharmaceutical industry

Silence's proprietary mRNAi GOLD platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.

Key Points: 
  • Silence's proprietary mRNAi GOLD platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.
  • Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Enpro Elects Judith A. Reinsdorf to Board of Directors

Retrieved on: 
Wednesday, September 1, 2021
Technology, Science, Other Science, Semiconductor, Monsanto, Financial compensation, Acquisition, Bradstreet, Dun & Bradstreet, Cornerstone, SIM NJ (Society for Information Management – New Jersey Chapter), Leadership, Tyco, Dun, Housing, Communities and Local Government Committee, Reinsdorf, Professional Football Compensation Committee, Alexion Pharmaceuticals, Pharmacia, NYSE, Crowell & Moring, JCI, Board, Johnson Controls, Tyco International, Food, NPO, Lawyer, C. R. Bard, CNR, Retirement, General counsel, AstraZeneca, Crowell, Management

EnPro Industries, Inc. (NYSE: NPO), an industrial technology company, has elected Judith A. Reinsdorf to the companys Board of Directors.

Key Points: 
  • EnPro Industries, Inc. (NYSE: NPO), an industrial technology company, has elected Judith A. Reinsdorf to the companys Board of Directors.
  • Ms. Reinsdorf was previously Executive Vice President and General Counsel at Johnson Controls (NYSE: JCI) until her retirement in 2017.
  • Currently, Reinsdorf is on the Compensation Committee at Cornerstone Building Brands (NYSE: CNR), serves on the advisory board of Teach for America New Jersey and the NACD New Jersey Chapter.
  • We welcome Judy to the Enpro Board, said David Hauser, Chairman of Enpro.

THE NATIONAL OVARIAN CANCER COALITION (NOCC) TO HOST ITS ANNUAL TOGETHER IN TEAL® - EVERYWHERE AS ONE NATIONAL BROADCAST CELEBRATION DURING SEPTEMBER AWARENESS MONTH ON SATURDAY, SEPTEMBER 25, 2021

Retrieved on: 
Wednesday, September 1, 2021
Ovarian cancer, LLC, Quality of life, Twitter, Instagram, AstraZeneca, Insperity, Quality, GLOBE, Merck & Co., TEAL, Social media, NOCC, Health, Cancer, Awareness, Safety, Volunteering, Cortec Group, Survivor, Patient, Outreach, Caregiver, LinkedIn, YouTube, Education, GSK, Birth control

Dallas, TX, Sept. 01, 2021 (GLOBE NEWSWIRE) -- During Ovarian Cancer Awareness Month, The National Ovarian Cancer Coalition (NOCC) will host its National Broadcast Celebration on Saturday, September 25th at 7 PM ET / 6 PM CT / 5 PM MT / 4 PM PT.

Key Points: 
  • Dallas, TX, Sept. 01, 2021 (GLOBE NEWSWIRE) -- During Ovarian Cancer Awareness Month, The National Ovarian Cancer Coalition (NOCC) will host its National Broadcast Celebration on Saturday, September 25th at 7 PM ET / 6 PM CT / 5 PM MT / 4 PM PT.
  • Sharing inspiration from coast to coast, this event will highlight the remarkable stories being told daily in communities across the nation.
  • NOCCs 2021 Together in TEAL - Everywhere As ONE campaign challenges the TEAL community to spread awareness and fundraise through weekly social media challenges.
  • About NOCC: Since 1991, the National Ovarian Cancer Coalition (NOCC) has provided support to thousands of cancer survivors, delivered millions of educational resources, and connected with countless local community partners to raise awareness about ovarian cancer.

Photocure appoints Anders Neijber as Vice President, Global Medical Affairs and Clinical Development

Retrieved on: 
Wednesday, September 1, 2021
Department, Technology, Senior management, Medical Affairs Bureau, Leadership, Drug, Western Michigan University, Oslo Stock Exchange, OSE, University of Michigan, Doctor of Philosophy, MBA, Patient, Solution, Novartis, Karolinska Institute, Anders, Bladder cancer, AstraZeneca, MD, Pharmaceutical industry, Management

OSLO, Norway, Sept. 1, 2021 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.

Key Points: 
  • OSLO, Norway, Sept. 1, 2021 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.
  • He held an Assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey.
  • In his new position, Anders Neijber will be a member of the Photocure Executive Leadership Team.
  • I look forward to his leadership leveraging his deep knowledge in the field of Urology and experience in leading a Global Medical Affairs strategy.

Photocure appoints Anders Neijber as Vice President, Global Medical Affairs and Clinical Development

Retrieved on: 
Wednesday, September 1, 2021
Department, Technology, Senior management, Medical Affairs Bureau, Leadership, Drug, Western Michigan University, Oslo Stock Exchange, OSE, University of Michigan, Doctor of Philosophy, MBA, Patient, Solution, Novartis, Karolinska Institute, Anders, Bladder cancer, AstraZeneca, MD, Pharmaceutical industry, Management

OSLO, Norway, Sept. 1, 2021 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.

Key Points: 
  • OSLO, Norway, Sept. 1, 2021 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.
  • He held an Assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey.
  • In his new position, Anders Neijber will be a member of the Photocure Executive Leadership Team.
  • I look forward to his leadership leveraging his deep knowledge in the field of Urology and experience in leading a Global Medical Affairs strategy.